Trump Signals Potential Changes to U.S. Cannabis Laws Amid New Health Warning
Donald Trump has expressed openness to revisiting U.S. cannabis laws after scientists identified a previously undocumented side effect linked to long-term use.
Patchwork of Cannabis Laws
Cannabis laws in the U.S. remain inconsistent. Federal law still classifies cannabis as a Schedule I controlled substance under the 1970 Controlled Substances Act. Yet, many states have introduced exemptions.
Medical use is widely accepted for conditions such as chronic pain, Multiple Sclerosis, and chemotherapy side effects, where it is often seen as less risky than opioids. Recreational use varies by state—some allow possession of small amounts, while others regulate where it can be consumed.
Trump’s Remarks
At a press conference earlier this year, Trump hinted at potential changes. He said:
“We’re looking at reclassification, and we’ll make a determination over the next—I would say, over the next few weeks, and that determination hopefully will be the right one.”
He added:
“It’s a very complicated subject. I’ve heard great things having to do with medical and bad things having to do with just about everything else.”
These comments signal that the administration is considering both medical benefits and risks associated with recreational use.
The New Health Warning: Cannabis Hyperemesis Syndrome
Trump’s statements follow new research identifying cannabis hyperemesis syndrome (CHS). This condition affects some long-term or regular users, causing severe nausea and vomiting.
Dr. Chris Buresh, an emergency medicine specialist, explained:
“Some people say they’ve used cannabis without a problem for decades. Or they smoke pot because they think it treats their nausea. It seems like there’s a threshold when people can become vulnerable to this condition, and that threshold is different for everyone. Even using in small amounts can make these people start throwing up.”
Implications for Law and Policy
Experts note that the emergence of CHS may influence lawmakers considering cannabis reclassification. As states continue to allow medical and recreational use, federal guidance may need to adjust to these new findings.
Trump’s remarks suggest a careful approach, weighing both the potential benefits for patients and the risks for recreational users.
The future of U.S. cannabis law may shift as federal authorities consider both medical advantages and newly identified health risks. CHS underscores the need for awareness among users, while Trump signals that reclassification could be on the horizon.
